The Pharmacy Times® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.
March 22nd 2024
The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Understanding the Mechanism of Action of Rucaparib in Cancer Treatment
February 24th 2022Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the mechanism of action of rucaparib in recurrent and second line ovarian cancer, fallopian tube cancer, and peritoneal cancer.
Watch
Trametinib Presents Potential New Standard-of-Care for Low-Grade Serous Ovarian Carcinoma
February 7th 2022Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.
Read More
Practice Pearl 3: Reducing Costs of PARPi for Ovarian Cancer Treatment
January 28th 2022Experts in gynecologic oncology provide insight on available patient assistance programs to help lower costs of PARP inhibitors for the treatment of ovarian cancer, and how pharmacists can aid in obtaining this information.
Watch
Practice Pearl 3: Provider Education of Emerging PARPi Data for Ovarian Cancer
January 21st 2022Sarah Hayward, PharmD, BCOP, leads the discussion on strategies used to keep the healthcare team well-informed and up to date on emerging data about PARP inhibitors for the treatment of ovarian cancer.
Watch
Practice Pearl 2: Improving Outcomes With PARPi Therapy in Ovarian Cancer
January 7th 2022Bradley J. Monk, MD, FACS, FACOG, and Jennifer MacDonald, PharmD, BCOP, share insight on improving outcomes and optimizing therapy with PARP inhibitors in the frontline maintenance setting for ovarian cancer.
Watch
Practice Pearl 2: Role of Pharmacists in Overcoming Access Barriers in Ovarian Cancer
January 7th 2022Bradley J. Monk, MD, FACS, FACOG, leads the discussion on the efficacy of currently approved PARP inhibitors used in the first-line maintenance setting for ovarian cancer and how pharmacists can help patients overcome access barriers.
Watch
Practice Pearl 1: Role of PARP Inhibitors in Ovarian Cancer
December 17th 2021Sarah Hayward, PharmD, BCOP; Jennifer MacDonald, PharmD, BCOP; and Bradley J. Monk, MD, FACS, FACOG, discuss the relevance of PARP inhibition in the treatment of ovarian cancer and comment on the use of biomarker testing for treatment initiation.
Watch
Study: 3% of Cancers In the US Preventable Through Weekly Physical Activity
November 2nd 2021Study finds that 16.9% of stomach cancers, 11.9% of endometrial cancers, 11.0% of kidney cancers, 9.3% of colon cancers, 8.1% of esophageal cancers, 6.5% of female breast cancers, and 3.9% of urinary bladder cancers were associated with a low level of exercise.
Read More
FDA Grants Fast Track Designation to STRO-002 for Advanced Ovarian Cancer
August 20th 2021STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.
Read More
FDA Grants Fast Track Designation to IN10018 for Treatment of Platinum-resistant Ovarian Cancer
August 17th 2021The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.
Read More
Education, Access Are Major Barriers to Genetic Testing for Breast, Ovarian Cancers
June 11th 2021Oncologist Susan Miesfeldt, MD, of MaineHealth, discussed the importance of genetic testing and counseling for breast and ovarian cancers as well as barriers that must be addressed in order to reach more patients eligible for these services.
Watch